The checkpoint 1 kinase inhibitor LY2603618 induces cell cycle arrest, DNA damage response and autophagy in cancer cells

Apoptosis

Volumn 19, Issue 9, 2014, Pages 1389-1398

  Wang, Feng Ze ^a   Fei, Hong Rong ^a   Cui, Ying Jie ^a   Sun, Ying Kun ^b   Li, Zhao Mei ^a   Wang, Xue Ying ^a   Yang, Xiao Yi ^a   Zhang, Ji Guo ^a   Sun, Bao Liang ^a  

^a TAISHAN MEDICAL UNIVERSITY   (China)

^b QINGDAO AGRICULTURAL UNIVERSITY   (China)

Author keywords

Autophagy; Chk1 inhibitor; DNA damage; G2 M phase; LY2603618

Indexed keywords

CASPASE 3; CHECKPOINT KINASE 2; CHLOROQUINE; HISTONE H2AX; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN P53; RABUSERTIB; STRESS ACTIVATED PROTEIN KINASE; ANTINEOPLASTIC AGENT; ANTIRHEUMATIC AGENT; CARBANILAMIDE DERIVATIVE; CASPASE; CHECKPOINT KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; MITOGEN ACTIVATED PROTEIN KINASE P38; NUCLEAR PROTEIN; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; PYRAZINE DERIVATIVE; SERINE;

APOPTOSIS; ARTICLE; AUTOPHAGY; AUTOPHOSPHORYLATION; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE M PHASE; CELL CYCLE PROGRESSION; CELL DEATH; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DNA DAMAGE; DRUG MECHANISM; HUMAN; HUMAN CELL; LUNG CANCER CELL LINE; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN PHOSPHORYLATION; CELL SURVIVAL; DNA REPAIR; DRUG EFFECTS; G2 PHASE CELL CYCLE CHECKPOINT; LUNG TUMOR; METABOLISM; NON SMALL CELL LUNG CANCER; PHOSPHORYLATION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; ANTIRHEUMATIC AGENTS; AUTOPHAGY; CARCINOMA, NON-SMALL-CELL LUNG; CASPASES; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHLOROQUINE; DNA DAMAGE; DNA REPAIR; G2 PHASE CELL CYCLE CHECKPOINTS; HUMANS; LUNG NEOPLASMS; MAP KINASE KINASE 4; NUCLEAR PROTEINS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHENYLUREA COMPOUNDS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PYRAZINES; SERINE;

EID: 84905740364     PISSN: 13608185     EISSN: 1573675X     Source Type: Journal    
DOI: 10.1007/s10495-014-1010-3     Document Type: Article

References (33)

1. Yi C, He C (2013) DNA repair by reversal of DNA damage. Cold Spring Harb Perspect Biol 5:a012575
2. Lagerwerf S, Vrouwe MG, Overmeer RM, Fousteri MI, Mullenders LH (2011) DNA damage response and transcription. DNA Repair (Amst) 10:743-750
3. Jun DW, Jeong YS, Kim HJ, Jeong KC, Kim S, Lee CH (2012) Characterization of DDRI-18 (3,3′-(1H,3′H-5,5′-bibenzo[d]imidazole-2,2′- diyl)dianiline), a novel small molecule inhibitor modulating the DNA damage response. Br J Pharmacol 167:141-150
4. Tao Y, Leteur C, Yang C et al (2009) Radiosensitization by Chir-124, a selective CHK1 inhibitor: effects of p53 and cell cycle checkpoints. Cell Cycle 8:1196-1205
5. Sperka T, Wang J, Rudolph KL (2012) DNA damage checkpoints in stem cells, ageing and cancer. Nat Rev Mol Cell Biol 13:579-590
6. Smith J, Tho LM, Xu N, Gillespie DA (2010) The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Adv Cancer Res 108:73-112
7. Enomoto M, Goto H, Tomono Y et al (2009) Novel positive feedback loop between Cdk1 and Chk1 in the nucleus during G2/M transition. J Biol Chem 284:34223-34230
8. Uto K, Inoue D, Shimuta K, Nakajo N, Sagata N (2004) Chk1, but not Chk2, inhibits Cdc25 phosphatases by a novel common mechanism. EMBO J 23:3386-3396 (Pubitemid 39209162)
9. 2 checkpoint inhibitor. Bioorg Med Chem Lett 22:2415-2417
10. Jiang X, Zhao B, Britton R et al (2004) Inhibition of Chk1 by the G2 DNA damage checkpoint inhibitor isogranulatimide. Mol Cancer Ther 3:1221-1227 (Pubitemid 39440167)
11. Wang XQ, Ongkeko WM, Chen L et al (2010) Octamer 4 (Oct4) mediates chemotherapeutic drug resistance in liver cancer cells through a potential Oct4-AKT-ATP-binding cassette G2 pathway. Hepatology 52:528-539
12. Rodríguez-Bravo V, Guaita-Esteruelas S, Salvador N, Bachs O, Agell N (2007) Different S/M Checkpoint Responses of Tumor and Non Tumor Cell Lines to DNA Replication Inhibition. Cancer Res 67:11648-11656
13. Dai Y, Chen S, Kmieciak M et al (2013) The novel Chk1 inhibitor MK-8776 sensitizes human leukemia cells to HDAC inhibitors by targeting the intra-S checkpoint and DNA replication and repair. Mol Cancer Ther 12:878-889
14. Borst GR, McLaughlin M, Kyula JN et al (2013) Targeted radiosensitization by the Chk1 inhibitor SAR-020106. Int J Radiat Oncol Biol Phys 85:1110-1118
15. Weiss GJ, Donehower RC, Iyengar T et al (2013) Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancer. Invest New Drugs 31:136-144
16. King C, Diaz H, Barnard D et al (2014) Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor. Invest New Drugs 32:213-226
17. Wei Y, Mizzen CA, Cook RG, Gorovsky MA, Allis CD (1998) Phosphorylation of histone H3 at serine 10 is correlated with chromosome condensation during mitosis and meiosis in Tetrahymena. Proc Natl Acad Sci USA 95:7480-7484 (Pubitemid 28293278)
18. Coumar MS, Tsai FY, Kanwar JR, Sarvagalla S, Cheung CH (2013) Treat cancers by targeting survivin: just a dream or future reality? Cancer Treat Rev 39:802-811
19. Hu F, Han J, Zhai B et al (2014) Blocking autophagy enhances the apoptosis effect of bufalin on human hepatocellular carcinoma cells through endoplasmic reticulum stress and JNK activation. Apoptosis 19:210-223
20. Moruno-Manchón JF, Pérez-Jiménez E, Knecht E (2013) Glucose induces autophagy under starvation conditions by a p38 MAPK-dependent pathway. Biochem J 449:497-506
21. Notte A, Ninane N, Arnould T, Michiels C (2013) Hypoxia counteracts taxol-induced apoptosis in MDA-MB-231 breast cancer cells: role of autophagy and JNK activation. Cell Death Dis 4:e638
22. Xiao Y, Ramiscal J, Kowanetz K et al (2013) Identification of preferred chemotherapeutics for combining with a CHK1 inhibitor. Mol Cancer Ther 12:2285-2295
23. Ng CP, Lee HC, Ho CW et al (2004) Differential mode of regulation of the checkpoint kinases CHK1 and CHK2 by their regulatory domains. J Biol Chem 279:8808-8819 (Pubitemid 38295939)
24. Wang X, Lui VC, Poon RT, Lu P, Poon RY (2009) DNA damage mediated s and g(2) checkpoints in human embryonal carcinoma cells. Stem Cells 27:568-576
25. Clarke CA, Clarke PR (2005) DNA-dependent phosphorylation of Chk1 and Claspin in a human cell-free system. Biochem J 388:705-712 (Pubitemid 40839948)
26. Kasahara K, Goto H, Enomoto M, Tomono Y, Kiyono T, Inagaki M (2010) 14-3-3 gamma mediates Cdc25A proteolysis to block premature mitotic entry after DNA damage. EMBO J 29:2802-2812
27. Parsels LA, Qian Y, Tanska DM et al (2011) Assessment of chk1 phosphorylation as a pharmacodynamic biomarker of chk1 inhibition. Clin Cancer Res 17:3706-3715
28. Riesterer O, Matsumoto F, Wang L et al (2011) A novel Chk inhibitor, XL-844, increases human cancer cell radiosensitivity through promotion of mitotic catastrophe. Invest New Drugs 29:514-522
29. Sharma A, Singh K, Almasan A (2012) Histone H2AX phosphorylation: a marker for DNA damage. Methods Mol Biol 920:613-626
30. Wang M, Morsbach F, Sander D et al (2011) EGF receptor inhibition radiosensitizes NSCLC cells by inducing senescence in cells sustaining DNA double-strand breaks. Cancer Res 71:6261-6269
31. Roberson RS, Kussick SJ, Vallieres E, Chen SY, Wu DY (2005) Escape from therapy-induced accelerated cellular senescence in p53-null lung cancer cells and in human lung cancers. Cancer Res 65:2795-2803 (Pubitemid 40490082)
32. Chifenti B, Locci MT, Lazzeri G et al (2013) Autophagy-related protein LC3 and Beclin-1 in the first trimester of pregnancy. Clin Exp Reprod Med 40:33-37
33. Chu PM, Chen LH, Chen MT et al (2012) Targeting autophagy enhances BO-1051-induced apoptosis in human malignant glioma cells. Cancer Chemother Pharmacol 69:621-633